von Neuhoff N - Search Results

1

Opposite expression pattern of Src kinase Lyn in acute and chronic haematological malignancies.

Hussein K, von Neuhoff N, Büsche G, Buhr T, Kreipe H, Bock O. Hussein K, et al. Among authors: von neuhoff n. Ann Hematol. 2009 Nov;88(11):1059-67. doi: 10.1007/s00277-009-0727-5. Epub 2009 Mar 17. Ann Hematol. 2009. PMID: 19290526 Free article.

2

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.

Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H. Hussein K, et al. Among authors: von neuhoff n. Exp Hematol. 2009 Oct;37(10):1186-1193.e7. doi: 10.1016/j.exphem.2009.07.005. Epub 2009 Jul 17. Exp Hematol. 2009. PMID: 19616600 Free article.

3

Leukemogenic potency of the novel FLT3-N676K mutant.

Huang K, Yang M, Pan Z, Heidel FH, Scherr M, Eder M, Fischer T, Büsche G, Welte K, von Neuhoff N, Ganser A, Li Z. Huang K, et al. Among authors: von neuhoff n. Ann Hematol. 2016 Apr;95(5):783-91. doi: 10.1007/s00277-016-2616-z. Epub 2016 Feb 19. Ann Hematol. 2016. PMID: 26891877

4

BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.

Gadzicki D, von Neuhoff N, Steinemann D, Just M, Büsche G, Kreipe H, Wilkens L, Schlegelberger B. Gadzicki D, et al. Among authors: von neuhoff n. Cancer Genet Cytogenet. 2005 Jun;159(2):164-7. doi: 10.1016/j.cancergencyto.2004.09.021. Cancer Genet Cytogenet. 2005. PMID: 15899391

5

Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia.

Buesche G, Ganser A, Schlegelberger B, von Neuhoff N, Gadzicki D, Hecker H, Bock O, Frye B, Kreipe H. Buesche G, et al. Among authors: von neuhoff n. Leukemia. 2007 Dec;21(12):2420-7. doi: 10.1038/sj.leu.2404917. Epub 2007 Sep 6. Leukemia. 2007. PMID: 17805334 Clinical Trial.

6

A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation.

Yang M, Pan Z, Huang K, Büsche G, Liu H, Göhring G, Rumpel R, Dittrich-Breiholz O, Talbot S, Scherr M, Chaturvedi A, Eder M, Skokowa J, Zhou J, Welte K, von Neuhoff N, Liu L, Ganser A, Li Z. Yang M, et al. Among authors: von neuhoff n. Leukemia. 2022 Mar;36(3):675-686. doi: 10.1038/s41375-021-01452-6. Epub 2021 Nov 3. Leukemia. 2022. PMID: 34732858 Free PMC article.

7

Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy.

Yang M, Pan Z, Huang K, Büsche G, Feuerhake F, Chaturvedi A, Nie D, Heuser M, Thol F, von Neuhoff N, Ganser A, Li Z. Yang M, et al. Among authors: von neuhoff n. Oncotarget. 2017 May 19;8(43):73871-73883. doi: 10.18632/oncotarget.18027. eCollection 2017 Sep 26. Oncotarget. 2017. PMID: 29088753 Free PMC article.

8

Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.

Suttorp M, Schulze P, Glauche I, Göhring G, von Neuhoff N, Metzler M, Sedlacek P, de Bont ESJM, Balduzzi A, Lausen B, Aleinikova O, Sufliarska S, Henze G, Strauss G, Eggert A, Kremens B, Groll AH, Berthold F, Klein C, Groß-Wieltsch U, Sykora KW, Borkhardt A, Kulozik AE, Schrappe M, Nowasz C, Krumbholz M, Tauer JT, Claviez A, Harbott J, Kreipe HH, Schlegelberger B, Thiede C. Suttorp M, et al. Among authors: von neuhoff n. Leukemia. 2018 Jul;32(7):1657-1669. doi: 10.1038/s41375-018-0179-9. Epub 2018 Jun 20. Leukemia. 2018. PMID: 29925908 Clinical Trial.

9

Exposure of Patient-Derived Mesenchymal Stromal Cells to TGFB1 Supports Fibrosis Induction in a Pediatric Acute Megakaryoblastic Leukemia Model.

Hack T, Bertram S, Blair H, Börger V, Büsche G, Denson L, Fruth E, Giebel B, Heidenreich O, Klein-Hitpass L, Kollipara L, Sendker S, Sickmann A, Walter C, von Neuhoff N, Hanenberg H, Reinhardt D, Schneider M, Rasche M. Hack T, et al. Among authors: von neuhoff n. Mol Cancer Res. 2020 Oct;18(10):1603-1612. doi: 10.1158/1541-7786.MCR-20-0091. Epub 2020 Jul 8. Mol Cancer Res. 2020. PMID: 32641517

10

Expression of the ETS transcription factor GABPα is positively correlated to the BCR-ABL1/ABL1 ratio in CML patients and affects imatinib sensitivity in vitro.

Manukjan G, Ripperger T, Santer L, von Neuhoff N, Ganser A, Schambach A, Schlegelberger B, Steinemann D. Manukjan G, et al. Among authors: von neuhoff n. Exp Hematol. 2015 Oct;43(10):880-90. doi: 10.1016/j.exphem.2015.05.011. Epub 2015 Jun 11. Exp Hematol. 2015. PMID: 26072332 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88 results

Search Page

Filters